Pharmaceutical services company, Open Orphan has signed a new contract, valued at €4.4m, with a global pharmaceutical company to provide a respiratory syncytial virus (RSV) human challenge study trial.
The Dublin-listed company specialises in the testing of vaccines and antivirals through the use of human challenge clinical trials.
This study will take place in Open Orphan's subsidiary hVIVO's London-based quarantine unit, and is expected to be completed by the end of quarter one 2021.
Cathal Friel, Executive Chairman, Open Orphan, said: "This contract, with a top 3 global pharmaceutical company, is evidence of the high regard hVIVO is held in within the industry and reinforces our position as the world leader in the testing of vaccines and antivirals using human challenge clinical trials," he said.
Mr Friel added, "As a group we are focused on winning and delivering high-quality, profitable contracts and this is another example of our delivery against that strategy."